{"id":"NCT01882439","sponsor":"Pfizer","briefTitle":"Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2013-06-20","resultsPosted":"2017-09-15","lastUpdate":"2017-09-15"},"enrollment":395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Tofacitinib","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Tofacitinib","otherNames":[]}],"arms":[{"label":"Treatment Sequence A","type":"EXPERIMENTAL"},{"label":"Treatment Sequence B","type":"EXPERIMENTAL"},{"label":"Treatment Sequence C","type":"PLACEBO_COMPARATOR"},{"label":"Treatment Sequence D","type":"PLACEBO_COMPARATOR"}],"summary":"To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.","primaryOutcome":{"measure":"Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (â‰¥) 20% (ACR20): Month 3","timeFrame":"Month 3","effectByArm":[{"arm":"Tofacitinib, 5 mg Twice Daily","deltaMin":49.62,"sd":null},{"arm":"Tofacitinib, 10 mg, Twice Daily","deltaMin":46.97,"sd":null},{"arm":"Placebo","deltaMin":23.66,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":125,"countries":["United States","Australia","Belgium","Brazil","Czechia","France","Germany","Mexico","Poland","Russia","Slovakia","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["40461265","40241921","37608391","36958766","36931693","36814062","36526796","36476498","36076054","36045453","35385361","35139908","34921355","34870800","34510295","34226183","33766074","32910531","32816215","32006348","31112005","31111255","30713722","30680661","30414064","30373651","29045207"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921125&StudyName=Tofacitinib%20In%20Psoriatic%20Arthritis%20Subjects%20With%20Inadequate%20Response%20to%20TNF%20Inhibitors"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":131},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Diarrhoea","Nausea"]}}